adalimumab
abbvie
['adalimumab']
surpass, first head-to-head in as, sec vs adalimumab biosimilar (sdz-adl) in active as. spinal radiographic progression over 2 years was low with no significant difference between sec and sdz-adl arms. no new safety signals. baraliakos #l15 #acr22 
MD PhD Consultant Rheumatologist &Physician,Assoc Medical Director,Digital Leader,NASS Trustee &Best Rheum Care,Visiting Fellow Henley Business School,ExecCoach